About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Fever After Tick Bite Study

Clinicaltrials.gov identifier NCT03932448

Recruitment Status Recruiting

First Posted April 30, 2019

Last update posted May 16, 2019

Study Description

Brief summary:

The proposed study is a collaboration between Microbiology, SU/Sahlgrenska and the Infectious Diseases clinic at SU/Östra as well as several Infectious Diseases clinics throughout Sweden aiming at improving microbiological diagnostic assays regarding the early identification of tick-borne microorganisms (including as of yet unidentified pathogens) capable of causing human disease using modern diagnostic tools. At the initial study visit (day 0) plasma, serum, urine, saliva, and PBMCs (and tick, if available) will be collected from patients developing fever within two weeks after a tick bite. Additional follow-up samples will be obtained after 9 and 30 days as well as after 6 months. The initial samples will be analyzed using (a) directed multiplex PCR analysis for Tick-Borne Encephalitis (TBE), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella, Tularemia, and Babesiosis in plasma, whole blood and urine, (b) conventional IgM and IgG serology for TBE, (c) "Next Generation Sequencing" (NGS) for the detection of bacterial 16s rRNA as well as unknown viruses, (d) potential biomarkers, and (e) host genetic factors. Among patients where initial sampling indicates the presence of a potential pathogen or in patients developing neurological symptoms, a lumbar puncture will be performed and CSF will be further analyzed. Samples will also be evaluated regarding potential microbiological factors predisposing for severity of infection. The primary objective of the study is to improve diagnostic tools in the initial early phase of infections caused by tick-borne pathogens, especially TBE prior to the affliction of the central nervous system, and to attempt to identify which factors impact the course of infection as it is believed that approximately 75% of infected individuals resolve their infection in this first phase whereas others develop meningoencephalitis with significant subsequent neurological sequelae. Secondary objectives of the study include investigating for the presence of and treating other tick-borne pathogens, setting the stage for coming clinical trials evaluating novel anti-viral therapies for TBE.

  • Condition or Disease:Tick Fever
    Tick-Bite; Fever
    Tick-Borne Diseases
    Encephalitis, Tick-Borne
    Tick Bites
  • Intervention/Treatment: Other: The proposed study is not interventional.
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 310 participants
  • Observational Model: Case-Only
  • Time Perspective: Prospective
  • Official Title: Fever After Tick Bite (FATB) Study; Determining the Etiology of Tick-Borne Human Infections in Northern Europe
  • Actual Study Start Date: May 2019
  • Estimated Primary Completion Date: December 2022
  • Estimated Study Completion Date: February 2023
Outcome Measures
  • Primary Outcome Measures: 1. Etiology of fever (≥38°C) developing within 2 weeks after a tick bite. [ Time Frame: Up to two weeks after the tick bite. ]
    Number of participants with detectable Tick-Borne Encephalitis Virus (TBEV), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella burnetii, Tularemia, and/or Babesia infections.
  • 2. Proportion of subjects developing neurological symptoms after a tick bite. [ Time Frame: Up to six months after the tick bite. ]
    The proportion of subjects developing neurological symptoms in each of the following etiological categories: Tick-Borne Encephalitis Virus (TBEV), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella burnetii, Tularemia, and/or Babesia.
  • 3. Proportion of subjects developing other serious, non-neurological symptoms or disease after a tick bite. [ Time Frame: Up to six months after the tick bite. ]
    The proportion of subjects developing other serious, non-neurological symptoms or disease in each of the following etiological categories: Tick-Borne Encephalitis Virus (TBEV), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella burnetii, Tularemia, and/or Babesia.
  • Secondary Outcome Measures: 1. Impact of body mass index (BMI) of subjects on the risk of development of neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of body mass index (weight and height will be combined to report BMI in kg/m2) of subjects developing vs. not developing neurological symptoms.
  • 2. Impact of waist circumference of subjects on the risk of development of neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of waist circumference (measured in cm) of subjects developing vs. not developing neurological symptoms.
  • 3. Impact of gender of subjects on the risk of development of neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of gender (male vs. female) of subjects developing vs. not developing neurological symptoms.
  • 4. Impact of age of subjects on the risk of development of neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of age (measured in years) of subjects developing vs. not developing neurological symptoms.
  • 5. Impact of body mass index of subjects developing other serious, non-neurological symptoms or disease. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of body mass index (weight and height will be combined to report BMI in kg/m2) of subjects developing vs. not developing other serious, non-neurological symptoms or disease.
  • 6. Impact of waist circumference of subjects developing other serious, non-neurological symptoms or disease. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of waist circumference (measured in cm) of subjects developing vs. not developing other serious, non-neurological symptoms or disease.
  • 7. Impact of gender of subjects developing other serious, non-neurological symptoms or disease. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of gender (male vs. female) of subjects developing vs. not developing other serious, non-neurological symptoms or disease.
  • 8. Impact of age of subjects developing other serious, non-neurological symptoms or disease. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of age (measured in years) of subjects developing vs. not developing other serious, non-neurological symptoms or disease.
  • 9. Prospective evaluation of the utility of Next Generation Sequencing (NGS) for the detection of unknown viruses and of bacterial 16s rRNA vs. directed Multiplex PCR [ Time Frame: Up to 30 days after the tick bite. ]
    Number of participants with Tick-Borne Encephalitis Virus (TBEV), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella burnetii, Tularemia, and/or Babesia infections as detected using Next Generation Sequencing (NGS) in comparison to Multiplex Polymerase Chain Reaction (Multiplex PCR).
  • 10. Prospective evaluation of the specificity and sensitivity of TBEV-RNA and TBE IgM serology in the early phase of infection, i.e. up to 30 days after the tick bite. [ Time Frame: Up to 30 days after the tick bite. ]
    Comparison of the number of subjects correctly identified as being infected with TBEV by means of analysis of TBEV-RNA vs. TBE IgM serology in the early phase of infection, i.e. up to 30 days after the tick bite.
  • 11. Prospective evaluation of the specificity and sensitivity of TBEV-RNA in urine vs. plasma/whole blood in the early phase of TBE infection, i.e. up to 30 days after the tick bite. [ Time Frame: Up to 30 days after the tick bite. ]
    Comparison of the number of subjects correctly identified as being infected with TBEV by means of analysis of TBEV-RNA in urine vs. plasma/whole blood in the early phase of TBE infection, i.e. up to 30 days after the tick bite.
  • 12. Prospective evaluation of the specificity and sensitivity of PCR for Borrelia DNA in plasma/serum as well as Borrelia IgM serology in the early phase of infection, i.e. up to 30 days after the tick bite. [ Time Frame: Up to 30 days after the tick bite. ]
    Comparison the number of subjects correctly identified as being infected with Borrelia by means of analysis of PCR for Borrelia DNA in plasma/serum as well as Borrelia IgM and IgG serology in the early phase of infection, i.e. up to 30 days after the tick bite.
  • 13. Prospective evaluation of the specificity and sensitivity of early evaluation of plasma concentrations of the neurological markers NFL in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of the neurological marker NFL will be evaluated among subjects developing vs. not developing neurological symptoms.
  • 14. Prospective evaluation of the specificity and sensitivity of early evaluation of plasma concentrations of the neurological marker T-tau in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of the neurological marker T-tau will be evaluated among subjects developing vs. not developing neurological symptoms.
  • 15. Prospective evaluation of the specificity and sensitivity of early evaluation of plasma concentrations of the neurological marker GFAp in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of neurological marker GFAp will be evaluated among subjects developing vs. not developing neurological symptoms.
  • 16. Prospective evaluation of the specificity and sensitivity of early evaluation of plasma concentrations of IP-10 (aka CXCL10) in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of IP-10 (aka CXCL10) will be evaluated among subjects developing vs. not developing neurological symptoms.
  • 17. Prospective evaluation of the specificity and sensitivity of early evaluation of 25-hydroxy vitamin D (25(OH)D) concentrations in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of 25-hydroxy vitamin D (25(OH)D) will be evaluated among subjects developing vs. not developing neurological symptoms.
  • 18. Prospective evaluation of peripheral blood mononuclear cells (PBMCs) analyzed by FACS, in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of the proportion of CD56 negative NK, CD4+ CD38+, CD8+ CD38+, CD8+CD16+, Foxp3+, and pDC (CD303+) cells analyzed by FACS will be evaluated among subjects developing vs. not developing neurological symptoms.
  • 19. Prospective evaluation of the impact of host genetic polymorphisms in the IFNL4 gene in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Proportion of subjects with genetic polymorphisms in the IFNL4 gene evaluated among subjects developing vs. not developing neurological symptoms.
  • 20. Prospective evaluation of the impact of host genetic polymorphisms in the ITPA gene in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Proportion of subjects with genetic polymorphisms in the ITPA gene evaluated among subjects developing vs. not developing neurological symptoms.
  • 21. Prospective evaluation of the impact of prior vaccination against TBE on frequency and outcome of TBEV infection. [ Time Frame: From time of prior vaccination until six months after the tick bite. ]
    Comparison of subjects with vs. without prior vaccination against TBE on frequency and outcome of TBEV infection.
  • 22. Prospective evaluation of the impact of prior vaccination against Yellow Fever on frequency and outcome of TBEV infection. [ Time Frame: From time of prior vaccination until six months after the tick bite. ]
    Comparison of subjects with vs. without prior vaccination against Yellow Fever on frequency and outcome of TBEV infection.
  • 23. Prospective evaluation of the impact of prior vaccination against Japanese Encephalitis on frequency and outcome of TBEV infection. [ Time Frame: From time of prior vaccination until six months after the tick bite. ]
    Comparison of subjects with vs. without prior vaccination against Japanese Encephalitis on frequency and outcome of TBEV infection.
  • 24. Prospective evaluation of the association between presence or absence of immunosuppression in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    The proportion of subjects with vs. without immunosuppression will be evaluated among subjects developing vs. not developing neurological symptoms.
  • Biospecimen Retention: Samples With DNA

    Plasma, serum, urine, saliva, and PBMCs will be sampled and stored.

Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Men and women ≥18 years old with documented or a medical history of fever (≥38°C) within 2 weeks after a tick bite.
Criteria

Inclusion Criteria:

- Written informed consent

- Male and female patients ≥18 years of age

- Medical history of tick bite within past 2 weeks

- Documented or medical history of fever (≥38°C) within past 2 weeks

Exclusion Criteria:

- Inability or unwillingness to provide informed consent or abide by the requirements of
the study

- Presence of urinary tract symptoms

- Presence of non-tick related, infectious agent causing fever, e.g. a respiratory virus

- Presence of other medical, non-infectious cause of fever

Contacts and Locations
Contacts

Contact: Martin Lagging, MD, PhD +46-(0)31-342 47 31 martin.lagging@medfak.gu.se

Contact: Marie Studahl, MD, PhD +46- (0)31-343 57 48 marie.studahl@infect.gu.se

Locations

Sweden
Dept. of Infectious Diseases
Gothenburg

Sponsors and Collaborators

Göteborg University

Sahlgrenska University Hospital, Sweden

Vastra Gotaland Region

Investigators

Principal Investigator: Martin Lagging, MD, PhD Göteborg University

More Information
  • Responsible Party: Göteborg University
  • ClinicalTrials.gov Identifier: NCT03932448 History of Changes
  • Other Study ID Numbers: FATB Study Group
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: May 16, 2019
  • Last Verified: May 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Undecided
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Tick-Borne Diseases
    Encephalitis, Tick-Borne
    Encephalitis
    Fever
    Bites and Stings
    Tick Bites